• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

The climate crisis and infectious diseases: what role for DNDi?

Home > Viewpoints

The climate crisis and infectious diseases: what role for DNDi?

Landscape photo from Argentina
12 Aug 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Over half of infectious diseases – including neglected ones such as dengue and leishmaniasis – are aggravated by climatic hazards, according to a new, devastating study published by Nature. We have yet to see the full impact of climate change on these climate-sensitive diseases, but one thing is sure: the most vulnerable populations will once again bear the brunt of a global crisis, warns Joelle Tanguy, Director of External Affairs at the Drugs for Neglected Diseases initiative (DNDi). 

She explains why DNDi has a critical role to play in supporting adaptation to the expected impacts of climate change. 

Joelle Tanguy
Joelle Tanguy, Director of External Affairs, DNDi

How serious is the impact of the climate crisis on health?  

Numerous studies have established that the climate crisis is the biggest health threat humanity is facing. Increased pollution, disruption of food systems, population displacements, and climate-sensitive infectious diseases will all have a devastating impact on people’s health around the world. The World Health Organization (WHO) estimates that between 2030 and 2050, climate change will cause 250,000 additional deaths per year from heat stress, malnutrition, dengue, and malaria alone.  

The emergence of zoonotic diseases (illnesses jumping from animals to humans) is facilitated by deforestation and damage to ecosystems. Higher temperatures combined with changes in land cover and increasing rainfall can make more areas suitable for the transmission of vector-borne diseases, and they can also lead to an increase in transmission through higher frequency of biting and an extended transmission season.  

All of this has been well documented in the latest report of the Intergovernmental Panel on Climate Change (IPCC, 2022).  

Take dengue: reported cases have increased by 85% in 30 years. Rising temperatures have led to increased survival and reproduction of the mosquitoes which carry the disease. The number of people at risk of dengue is predicted to reach 60% of the world’s population by 2080.

What risks do climate-sensitive diseases pose? How will people’s health be affected?  

These are difficult questions. There are serious evidence gaps on the impact of the climate crisis on the epidemiology of neglected diseases, and more research is needed.  

What we know for sure is that the people who will be disproportionately affected by climate-sensitive diseases will be, once again, the poorest and the most vulnerable. The climate crisis will bring further immense suffering to an increasing number of already neglected people – and to their families and communities. Climate change acts as a ‘poverty multiplier’ that forces millions into poverty because of diseases, but also loss of livelihoods, displacement, and lack of access to food and clean water. 

According to estimates, the number of people exposed to leishmaniasis may double by 2080. In central Africa, the 55 million people at risk of sleeping sickness could increase by a similar range by 2090. 

Whilst we are already seeing some neglected diseases spreading to new areas in the global north, such as Chagas disease in Spain or the United States, the brunt of the impact is projected to take place in low- and middle-income countries (LMICs).  

We need to act now to develop better medical tools for these already neglected populations. Such tools include drugs, but also diagnostics, vaccines, and vector control measures – as one single tool is not enough for effective disease control and elimination. 

Is the current medical and pharmaceutical ecosystem ready to tackle these global health challenges? 

There is a pressing need to prioritize R&D for climate-sensitive diseases for which drugs and diagnostics are not developed or are not available, as the medical and pharmaceutical industry focuses on more profitable markets. This has historically been the case with neglected tropical diseases (NTDs). 

And even where there is innovation, the last two and a half years have shown that during an emergency, in the middle of a global pandemic, the most vulnerable do not have access to life-saving prevention and treatment tools. COVID-19 vaccines were developed at an unprecedented speed, but they did not reach most people who needed them in many LMICs.  

Unless we act, we will face the same issue of innovation and access inequity with the looming climate crisis. We cannot afford to repeat the NTD experience or have another HIV or COVID-19 moment, when we find ourselves with few or very expensive drugs or vaccines, reserved for the wealthy. We need to act now to prevent history from repeating itself again, or it will be too late.

‘Few are connecting the dots between climate change and the need for medical R&D. Innovation to find new medicines must be an integral part of climate adaptation efforts.’

Joelle Tanguy, Director of External Affairs, DNDi

We are therefore investing in efforts to discover and develop drugs for climate-sensitive NTDs such as leishmaniasis and dengue with academic, public, and industry partners, especially from the Global South; but we are also engaging in policy discussions and advocating for a more equitable, inclusive, sustainable, and access-oriented R&D ecosystem. 

Access must be considered from step one when developing a new drug. The needs of the target populations and health systems, and the necessity to produce affordably and at scale must be fully integrated in the pharmaceutical R&D process. For example, a complex injectable drug that requires weeks of hospitalization would be difficult to administer in remote or resource-limited settings. 

We need to start from today designing an innovation system in such a way that public investments made in academia, in the pharma industry, in hospital capacity for clinical trials, reap the rewards in terms of public health and help build climate resilience. 

We also need to ensure that the medical R&D agenda is included in climate change discussions and bring the topic to high-level meetings. Few are connecting the dots between climate change and the need for medical R&D. Innovation to find new medicines must be an integral part of climate adaptation efforts.  

What is DNDi’s approach to the climate crisis? 

DNDi is developing a four-pronged approach, to power both mitigation and adaptation to the climate crisis. 

First, innovation: we will discover and develop new, adapted, and affordable treatments for climate-sensitive diseases for neglected patients. Many infectious diseases affected by the climate crisis are already in our R&D portfolio. 

Second, greening R&D: we want to proactively contribute to the movement for greening pharmaceutical R&D and manufacturing practices. 

Third, advocating for a responsible biomedical innovation ecosystem. We will advocate for an inclusive and sustainable R&D system and climate adaptation policies that ensure innovation, affordability, and equitable access for all people affected by climate-sensitive, vector-borne diseases, wherever they are.  

And fourth, halving our carbon emissions and our environmental footprint by 2030. To reach that target, we are developing an environmental roadmap in collaboration with our allies, and in dialogue with our pharmaceutical development partners.  

I would like to highlight that our work is not peripheral to the climate issue. Human health needs to be a major pillar of the climate adaptation agenda so that countries are ready for what is coming, and what is already here.  

Because of what we do, because of our ambition to deliver 25 new treatments by 2028, DNDi is at the forefront of climate adaptation strategies to respond effectively to the climate crisis, possibly the greatest challenge humanity has ever faced.   

Photo credit: Ana Ferreira-DNDi

Climate change

Read, watch, share

Loading...
Woman standing in front of a house
Press releases
2 Feb 2023

Dutch government renews support to DNDi projects on poverty-related diseases that disproportionately impact women

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo